Back to News
Market Impact: 0.38
McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal
Source: marketbeat.com
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsHealthcare & Biotech
McKesson said first-quarter performance supported an increase to its full-year earnings outlook. Growth was broad-based across its North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions businesses, signaling sustained operating momentum across its core healthcare distribution platforms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
Ticker Sentiment
MCK0.72
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- RBC Capital cuts Sprouts Farmers Market stock rating on margin concerns
- Microsoft's Big Bets on AI Start to Pay Off